NCT05286879 (ACTION) is a NA clinical trial of Patient Navigator in Opioid Use Disorder, sponsored by Yale University.

Who is sponsoring NCT05286879?

NCT05286879 is sponsored by Yale University.

What drugs are being tested in NCT05286879?

Interventions in NCT05286879: Patient Navigator, Mobile Health Unit.

What condition does NCT05286879 study?

NCT05286879 studies Opioid Use Disorder, Infectious Disease, Risk Reduction Behavior, Substance Use, Substance Abuse, Stimulant Use Disorder.

Is NCT05286879 still recruiting?

NCT05286879 is currently completed. Last updated 2 April 2026.

Last reviewed 2026-04-02 · How we verify

NCT05286879: ACTION

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations

Completed NA Last updated 2 April 2026

What this trial tests

NA trial testing Patient Navigator in Opioid Use Disorder in 600 participants. Completed in 12 December 2025.

Timeline

31 March 2022

Primary endpoint
31 July 2025

12 December 2025

Quick facts

Lead sponsor	Yale University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	600
Start date	31 March 2022
Primary completion	31 July 2025
Estimated completion	12 December 2025
Sites	3 locations across United States

Drugs / interventions tested

Patient Navigator
Mobile Health Unit

Conditions studied

Opioid Use Disorder — all drugs for Opioid Use Disorder →
Infectious Disease — all drugs for Infectious Disease →
Risk Reduction Behavior — all drugs for Risk Reduction Behavior →
Substance Use — all drugs for Substance Use →

Sponsor

Yale University

Who can join

18 and older, any sex, with Opioid Use Disorder or Infectious Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a 5-year Hybrid Type 1 Effectiveness-Implementation Randomized Control Trial (RCT) that compares two models of linking and retaining individuals recently released from justice involvement to the continuum of community-based HIV prevention and treatment, HCV treatment, STI treatment, and opioid use disorder (OUD) prevention and treatment, medication for opioid use disorder (MOUD) service cascades of care.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Study protocol of a randomized controlled trial comparing two linkage models for HIV prevention and treatment in justice-involved persons.
Springer SA, Nijhawan AE, Knight K, Kuo I, et al · · 2022 · cited 16× · PMID 35428213 · DOI 10.1186/s12879-022-07354-x
HIV Risk and Interest in Preexposure Prophylaxis in Justice-Involved Persons.
Nijhawan AE, Pulitzer Z, Torres B, Noreen N, et al · · 2024 · cited 5× · PMID 38561803 · DOI 10.3201/eid3013.230739
A qualitative examination of barriers and facilitators to HIV prevention and treatment for people involved with the criminal justice system.
Villaire S, Sease T, Pankow J, Bennett A, et al · · 2025 · PMID 40478391 · DOI 10.1186/s40352-025-00344-6

Verify or expand the search:

Other trials of Patient Navigator

Trials testing the same drug.

NCT03451552 — Patient Navigation in Primary Care and Access to Resources in the Community · NA · completed
NCT03342495 — Evaluating Innovations in Transition From Pediatric to Adult Care - The Transition Navigator Trial · NA · completed
NCT01917747 — Promoting Early Diagnosis of Congenital Hearing Loss With Patient Navigators · NA · completed

Other recruiting trials for Opioid Use Disorder

Currently open trials in the same condition.

NCT07278518 — Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine · NA · recruiting
NCT07044466 — Social Functioning in Opioid Use Disorder · NA · recruiting
NCT07158853 — Combined tDCS and Cognitive Training as an Adjunctive Treatment in Opioid Use Disorder · NA · recruiting
NCT06943859 — Ketamine for Opioid Use Disorder · Phase 2 · recruiting
NCT06651177 — Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder · Phase 2 · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05286879 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 2 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05286879.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing